Cardiovascular disease is the number one cause of death in the industrialized world. Much of the morbidity and mortality from heart disease can be linked to elevated low-density lipoprotein (LDL) cholesterol, and one of the key genes that increases LDL cholesterol is Proprotein convertase subtilisin/kexin type 9 (PCSK9). In a recent study in nonhuman primates, Lindholm et al. demonstrate that a 1 month course of weekly subcutaneous therapy with either of two locked nucleic acid (LNA) antisense oligonucleotides targeting PCSK9 rapidly decreases the expression of both PCSK9 and circulating LDL cholesterol without reported toxicity.1 The reduction in serum LDL is sustained for more than a month after the last dose of the LNA antisense.